HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis

G. Tincknell; A. Naveed; J. Nankervis; A. Mukhtiar; A.-K. Piper; Therese M. Becker; L. Chantrill; M. Aghmesheh; K.L. Vine; M. Ranson; D. Brungs

doi:10.3390/cancers14235754

HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis

G. Tincknell, A. Naveed, J. Nankervis, A. Mukhtiar, A.-K. Piper, Therese M. Becker, L. Chantrill, M. Aghmesheh, K.L. Vine, M. Ranson, D. Brungs

Western Sydney University

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs. The association of HER2 with GOC brain metastasis is not known. We performed a retrospective analysis of patients with GOCs with known HER2 status between January 2015 and November 2021. HER2 was assessed on either the primary tumour or metastasis by immunohistochemistry or in situ hybridization. The diagnosis of brain metastasis was made on standard imaging techniques in patients with symptoms or signs. HER2 results were available for 201 patients, with 34 patients (16.9%) HER2 positive. A total of 12 patients developed symptomatic brain metastasis from GOCs, of which 7 (58.3%) were HER2 positive. The development of symptomatic brain metastasis was significantly higher in the HER2-positive GOCs (OR8.26, 95%CI 2.09-35.60; p = 0.0009). There was no significant association of HER2 status and overall survival in patients with brain metastasis. Although the rate of brain metastasis remains low in GOCs, the incidence of symptomatic brain metastasis was significantly higher in patients with HER2-positive tumours.

Original language	English
Article number	5754
Number of pages	14
Journal	Cancers
Volume	14
Issue number	23
DOIs	https://doi.org/10.3390/cancers14235754
Publication status	Published - 2022

Open Access - Access Right Statement

© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/cancers14235754

Cite this

@article{3d469c29636e44cf9c7b068138f7637e,

title = "HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis",

abstract = "Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs. The association of HER2 with GOC brain metastasis is not known. We performed a retrospective analysis of patients with GOCs with known HER2 status between January 2015 and November 2021. HER2 was assessed on either the primary tumour or metastasis by immunohistochemistry or in situ hybridization. The diagnosis of brain metastasis was made on standard imaging techniques in patients with symptoms or signs. HER2 results were available for 201 patients, with 34 patients (16.9%) HER2 positive. A total of 12 patients developed symptomatic brain metastasis from GOCs, of which 7 (58.3%) were HER2 positive. The development of symptomatic brain metastasis was significantly higher in the HER2-positive GOCs (OR8.26, 95%CI 2.09-35.60; p = 0.0009). There was no significant association of HER2 status and overall survival in patients with brain metastasis. Although the rate of brain metastasis remains low in GOCs, the incidence of symptomatic brain metastasis was significantly higher in patients with HER2-positive tumours.",

author = "G. Tincknell and A. Naveed and J. Nankervis and A. Mukhtiar and A.-K. Piper and Becker, {Therese M.} and L. Chantrill and M. Aghmesheh and K.L. Vine and M. Ranson and D. Brungs",

year = "2022",

doi = "10.3390/cancers14235754",

language = "English",

volume = "14",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "23",

}

TY - JOUR

T1 - HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis

AU - Tincknell, G.

AU - Naveed, A.

AU - Nankervis, J.

AU - Mukhtiar, A.

AU - Piper, A.-K.

AU - Becker, Therese M.

AU - Chantrill, L.

AU - Aghmesheh, M.

AU - Vine, K.L.

AU - Ranson, M.

AU - Brungs, D.

PY - 2022

Y1 - 2022

N2 - Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs. The association of HER2 with GOC brain metastasis is not known. We performed a retrospective analysis of patients with GOCs with known HER2 status between January 2015 and November 2021. HER2 was assessed on either the primary tumour or metastasis by immunohistochemistry or in situ hybridization. The diagnosis of brain metastasis was made on standard imaging techniques in patients with symptoms or signs. HER2 results were available for 201 patients, with 34 patients (16.9%) HER2 positive. A total of 12 patients developed symptomatic brain metastasis from GOCs, of which 7 (58.3%) were HER2 positive. The development of symptomatic brain metastasis was significantly higher in the HER2-positive GOCs (OR8.26, 95%CI 2.09-35.60; p = 0.0009). There was no significant association of HER2 status and overall survival in patients with brain metastasis. Although the rate of brain metastasis remains low in GOCs, the incidence of symptomatic brain metastasis was significantly higher in patients with HER2-positive tumours.

AB - Brain metastasis from gastroesophageal adenocarcinomas (GOCs) is a rare but a devastating diagnosis. Human epidermal growth factor receptor 2 (HER2) is a prognostic and predictive biomarker in GOCs. The association of HER2 with GOC brain metastasis is not known. We performed a retrospective analysis of patients with GOCs with known HER2 status between January 2015 and November 2021. HER2 was assessed on either the primary tumour or metastasis by immunohistochemistry or in situ hybridization. The diagnosis of brain metastasis was made on standard imaging techniques in patients with symptoms or signs. HER2 results were available for 201 patients, with 34 patients (16.9%) HER2 positive. A total of 12 patients developed symptomatic brain metastasis from GOCs, of which 7 (58.3%) were HER2 positive. The development of symptomatic brain metastasis was significantly higher in the HER2-positive GOCs (OR8.26, 95%CI 2.09-35.60; p = 0.0009). There was no significant association of HER2 status and overall survival in patients with brain metastasis. Although the rate of brain metastasis remains low in GOCs, the incidence of symptomatic brain metastasis was significantly higher in patients with HER2-positive tumours.

UR - https://hdl.handle.net/1959.7/uws:74778

U2 - 10.3390/cancers14235754

DO - 10.3390/cancers14235754

M3 - Article

SN - 2072-6694

VL - 14

JO - Cancers

JF - Cancers

IS - 23

M1 - 5754

ER -

HER2-positive gastroesophageal cancers are associated with a higher risk of brain metastasis

Abstract

Open Access - Access Right Statement

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this